Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,636
datasets available to search
ShareScore release 0.9.0
Dataset results
1,636 results for “Head and neck cancer;”
Super-enhancer driven LIF/LIFR-STAT3-SOX2 regulatory feedback loop promotes cancer stemness in head and neck squamous cell carcinoma (ChIP-seq)
GEO Series GSE274995. Homo sapiens. 3 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Identification of GNG7 as An Epigenetically Silenced Gene in Head and Neck Cancer by Gene Expression Profiling
GEO Series GSE29330. Homo sapiens. 18 samples. Type: Expression profiling by array.
Expression data from ALDH2 knockdown in head and neck cancer cells.
GEO Series GSE253622. Homo sapiens. 2 samples. Type: Expression profiling by array.
Gene expression profiling in HPV-infected oropharyngeal head and neck cancer
GEO Series GSE163173. Homo sapiens. 286 samples. Type: Expression profiling by array.
A Novel Orthotopic Mouse Model of Head and Neck Cancer and Lymph Node Metastasis
GEO Series GSE41893. Homo sapiens. 12 samples. Type: Expression profiling by array.
NFE2L2 mutations enhance radioresistance in head and neck cancer by modulating intratumoral myeloid cells
GEO Series GSE222658. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.
In vivo CRISPR screens in Head and Neck Cancer reveal that Uchl5 modulates extracellular matrix deposition to promote immune evasion [in vitro]
GEO Series GSE269444. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Recurrent human papillomavirus-related head and neck cancer undergoes metabolic re-programming and is driven by oxidative phosphorylation
GEO Series GSE165883. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
Piezoeletric cold atmospheric plasma sensitizes head and neck cancer to chemotherapy and immune checkpoint blockade therapy
GEO Series GSE235832. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.
In vivo CRISPR screens in Head and Neck Cancer reveal that Uchl5 modulates extracellular matrix deposition to promote immune evasion [in vivo]
GEO Series GSE269445. Mus musculus. 11 samples. Type: Expression profiling by high throughput sequencing.
Unraveling cetuximab response in head and neck cancer with APHRODYTHE, a multi-omics patient-derived xenograft platform
GEO Series GSE317901. Homo sapiens. 114 samples. Type: Expression profiling by high throughput sequencing.
Integration of p16/HPV DNA status with a 24-miRNA-defined molecular phenotype improves clinically relevant stratification of head and neck cancer patients
GEO Series GSE175509. Homo sapiens. 229 samples. Type: Non-coding RNA profiling by array.
Impact of gas plasma-induced chronic oxidative stress on head and neck cancer
GEO Series GSE223042. Homo sapiens. 20 samples. Type: Expression profiling by array.
Corelation between RISC complex, LINE-1 RNA and Global hypomethylation in head and Neck cancer cell line.
GEO Series GSE33493. Homo sapiens. 24 samples. Type: Expression profiling by array.
Dataset related to article "Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics."
<p>PURPOSE:</p> <p>To appraise the ability of a radiomics signature to predict clinical outcome after definitive radiochemotherapy (RCT) of stage III-IV head and neck cancer.</p> <p>METHODS:</p> <p>A cohort of 110 patients was included in a retrospective analysis. Radiomics texture features were extracted from the gross tumor volumes contoured on planning computed tomography (CT) images. The cohort of patients was randomly divided into a training (70 patients) and a validation (40 patients) cohorts. Textural features were correlated to survival and control data to build predictive models. All the significant predictors of the univariate analysis were included in a multivariate model. The quality of the models was appraised by means of the concordance index (CI).</p> <p>RESULTS:</p> <p>A signature with 3 features was identified as predictive of overall survival (OS) with CI = 0.88 and 0.90 for the training and validation cohorts, respectively. A signature with 2 features was identified for progression-free survival (PFS; CI = 0.72 and 0.80); 2 features also characterized the signature for local control (LC; CI = 0.72 and 0.82). In all cases, the stratification in high- and low-risk groups for the training and validation cohorts led to significant differences in the actuarial curves. In the validation cohort the mean OS times (in months) were 78.9 ± 2.1 vs 67.4 ± 6.0 in the low- and high-risk groups, respectively, the PFS was 73.1 ± 3.7 and 50.7 ± 7.2, while the LC was 78.7 ± 2.1 and 63.9 ± 6.5.</p> <p>CONCLUSION:</p> <p>CT-based radiomic signatures that correlate with survival and control after RCT were identified and allow low- and high-risk groups of patients to be identified.</p>
Dataset related to article "Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients."
<p>OBJECTIVE:</p> <p>To analyze two cohorts of locally advanced head and neck cancer (LAHNC) patients treated with two schedules of hypofractionated radiotherapy and 5 versus 3 mm clinical target volume-planning target volume (CTV-PTV) margins.</p> <p>METHODS:</p> <p>145 patients were included. The patient cohort was divided into two groups. Group A included 97 patients treated with 69.96/54.45 grays (Gy) to the high-risk and low-risk volumes, respectively, in 33 fractions, with 5 mm margins. Group B included 48 patients treated with 66/54 Gy in 30 fractions using 3 mm margins. Toxicity was recorded according to the Common Toxicity Criteria version 3. Patient outcomes for locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) were determined.</p> <p>RESULTS:</p> <p>Median follow-up was 26 months. In terms of toxicity, acute dysphagia worsened significantly (P = 0.003) in group B, whereas acute salivary toxicity tended to significance (P = 0.071). No significant late toxicity differences were recorded. Rates of LRC at 1 and 2 years were 90.1% ± 2.6% and 84.2% ± 3.4%, respectively, with superiority for group A (P = 0.045). The statistical significance remained for the low-dose level (P = 0.007) but not for high dose (P = 0.110). Rates of DFS at 1 and 2 years were 84.9% ± 3.1% and 76.5% ± 3.9%, respectively, whereas rates of OS were 95.9% ± 1.8% and 91.6% ± 2.7%, respectively. No differences were observed between the two groups in terms of DFS (P = 0.270) and OS (P = 0.152).</p> <p>CONCLUSION:</p> <p>The use of reduced CTV to PTV margins and dose reduction with hypofractionation schedule can improve the pattern of toxicity in LAHNC patients. This approach resulted in an increased rate of locoregional progression, particularly in low-risk regions.</p> <p>LEVEL OF EVIDENCE:</p> <p>4 Laryngoscope, 2019.</p>
Dataset related to article "Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer"
<p>This record contains raw data related to article "Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer"</p> <p><strong>Introduction: </strong>Recently major efforts have been made to define the oligometastatic setting, but for head and neck cancer (HNC) limited data are available. We aimed to evaluate outcome of oligometastatic HNC treated with Stereotactic body radiotherapy (SBRT) as metastasis-directed therapy.</p> <p><strong>Materials and methods: </strong>We analyzed patients treated with SBRT on a maximum of five oligometastases from HNC, in up to two organs. Concomitant treatment was allowed. End points were toxicity, local control of treated metastases (LC), progression-free survival (PFS) and overall survival (OS).</p> <p><strong>Results: </strong>48 consecutive patients and 71 lesions were treated. With a follow-up of 20.2 months, most common primary tumors were larynx (29.2%) and salivary glands (29.2%), while common site of metastases was lung (59.1%). Median dose was 48 Gy (21-75) in 3-8 fractions. Treatment was well tolerated, with two patients reporting mild pain and nausea. LC rates at 1 and 2 years were 83.1% and 70.2%. Previous local therapy (HR 4.97; p = 0.002), oligoprogression (HR 4.07; p = 0.031) and untreated metastases (HR 4.19; p = 0.027) were associated with worse LC. PFS at 1 and 2 years were 42.2% and 20.0%. Increasing age (HR 1.03; p = 0.010), non-adenoid cystic carcinoma (HR 2.57; p = 0.034) and non-lung metastases (HR 2.20; p = 0.025) were associated with worse PFS. One- and 2-years OS were 81.0% and 67.1%. Worse performance status (HR 2.91; p = 0.049), non-salivary primary (HR 19.9; p = 0.005), non-lung metastases (HR 2.96; p = 0.040) were correlated with inferior OS.</p> <p><strong>Conclusions: </strong>SBRT can be considered a safe metastasis-directed therapy in oligometastatic HNC. Efficacy of the treatment seems to be higher when administered upfront in the management of metastatic disease; however, selection of patients need to be improved due to the relevant risk of appearance of new metastatic site after SBRT.</p>
Dataset related to article "An approach to evaluate the quality of radiological reports in Head and Neck cancer loco-regional staging: experience of two Academic Hospitals "
<p>This record contains raw data related to article “An approach to evaluate the quality of radiological reports in Head and Neck cancer loco-regional staging: experience of two Academic Hospitals"</p> <p>Abstract</p> <p><strong>Objectives: </strong> To evaluate the quality of the reports of loco-regional staging computed tomography (CT) or magnetic resonance imaging (MRI) in head and neck (H&N) cancer.</p> <p><strong>Methods: </strong> Consecutive reports of staging CT and MRI of all H&N cancer cases from 2018 to 2020 were collected. We created lists of quality indicators for tumor (T) for each district and for node (N). We marked these as 0 or 1 in the report calculating a report score (RS) and a maximum sum (MS) of each list. Two radiologists and two otolaryngologists in consensus classified reports as low quality (LQ) if the RS fell in the percentage range 0-59% of MS and as high quality (HQ) if it fell in the range 60-100%, annotating technique and district. We evaluated the distribution of reports in these categories.</p> <p><strong>Results: </strong> Two hundred thirty-seven reports (97 CT and 140 MRI) of 95 oral cavity, 52 laryngeal, 47 oropharyngeal, 19 hypo-pharyngeal, 14 parotid, and 10 nasopharyngeal cancers were included. Sixty-six percent of all the reports were LQ for T, 66% out of all the MRI reports, and 65% out of all CT reports were LQ. Eight-five percent of reports were HQ for N, 85% out of all the MRI reports, and 82% out of all CT reports were HQ. Reports of oral cavity, oro-nasopharynx, and parotid were LQ, respectively, in 76%, 73%, 100% and 92 out of cases.</p> <p><strong>Conclusion: </strong> Reports of staging CT/MRI in H&N cancer were LQ for T description and HQ for N description.</p>
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
ClinicalTrials.gov study NCT00095641. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck
ClinicalTrials.gov study NCT00363441. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.